Introduction {#sec1}
============

Immunoglobin G4-related disease (IgG4-RD) is a systemic immune-mediated disease which affects various organs, predominantly the pancreas, bile ducts and salivary glands.[@bib1] IgG4-RD of the pancreas (auto-immune pancreatitis \[AIP\] type 1) and the bile ducts (IgG4-related cholangitis, IRC) are benign inflammatory diseases which are responsive to corticosteroid treatment.[@bib2]^,^[@bib3] Diagnostic criteria such as the HISORt criteria including histopathological (H), imaging (I), serological (S) features, other organ manifestations of IgG4-RD (O) and response to treatment (Rt), have been developed to diagnose pancreatobiliary IgG4-RD.[@bib3] Still, the accuracy of these diagnostic criteria is limited and AIP type I and IRC remain difficult to distinguish from pancreatobiliary malignancies or primary/secondary sclerosing cholangitis.[@bib4]^,^[@bib5] Clinical signs and symptoms of obstructive jaundice, weight loss and abdominal discomfort are frequently seen in AIP and IRC as well as in pancreatobiliary malignancies. On imaging, pancreatic mass and biliary strictures or mass-forming lesions are seen in both conditions as well.[@bib3] Unfortunately, misdiagnosis is common and may result in unnecessary surgical interventions or systemic chemotherapy in patients with IgG4-RD. The rate of unexpected benign disease after hemihepatectomy for presumed cholangiocarcinoma or pancreatoduodenectomy for presumed pancreatic ductal carcinoma still ranges from 5 to 15%,[@bib6], [@bib7], [@bib8] with IgG4-RD being a major contributor.[@bib8] Remarkably, up to a third of patients with IgG4-RD may undergo major surgery due to presumed malignancy prior to an accurate diagnosis of IgG4-RD.[@bib9] IgG4 serum levels have limited diagnostic value when only modestly elevated (\<4x the upper limit of normal), since 10--15% of patients with pancreatobiliary cancers and primary sclerosing cholangitis (PSC) may also exhibit increased IgG4 serum levels.[@bib10], [@bib11], [@bib12] Moreover, up to 30% of patients with IgG4-related pancreatobiliary disease have normal serum IgG4 levels.[@bib3]^,^[@bib13] Histo- or cytopathological confirmation of malignancy is often difficult to obtain, particularly of a hilar mass, and histological differentiation between benign and malignant pancreatobiliary entities can be challenging. Elevated carbohydrate antigen (CA) 19.9 level is not sufficient to differentiate between benign and malignant pancreatobiliary disease with obstructive jaundice.[@bib14]

Our group recently proposed blood IgG4/IgG RNA ratio, determined by quantitative PCR (qPCR), as a diagnostic test to discriminate IgG4-RD from PSC or pancreatobiliary cancer[@bib12] based on the high accuracy (94% sensitivity; 99% specificity) of this test for distinguishing patients with IgG4-RD from those with PSC and biliary/pancreatic cancer.[@bib12] The present study aimed to detect IgG4-RD in patients presented consecutively with suspected biliary or pancreatic cancer, in order to prevent misdiagnosis by determining the blood IgG4/IgG RNA ratio by qPCR for the diagnosis of IgG4-RD.

Patients and methods {#sec2}
====================

In this prospective, observational, single center study, all consecutive patients of ≥18 years of age presenting at a specialized multidisciplinary hepato-pancreato-biliary clinic, at the Amsterdam UMC, with suspected or proven biliary or pancreatic cancer were included between February 21^st^ and September 4^th^, 2019. Standard diagnostic procedures were performed including laboratory assessment (hemoglobin, mean corpuscular volume, leukocytes, erythrocytes, platelets, creatinine, albumin, blood urea nitrogen, glucose, potassium, sodium, total bilirubin, alkaline phosphatase, gamma-glutamyltransferase, alanine aminotransferase, aspartate aminotransferase, prothrombin time, CA19.9, IgG and IgG4), radiographic imaging (ultrasound, CT and/or MRI) and histo-/cytopathological analysis. In addition, the blood IgG4/IgG RNA ratio was determined and considered positive if the ratio was \>5.0%.[@bib12]

The exact method for determining the IgG4/IgG RNA ratio has been extensively described.[@bib12] In brief, RNA was isolated from peripheral blood and processed. Complementary DNA (cDNA) was synthesized from RNA using Superscript III RT (Invitrogen Life Technologies, Carlsbad, CA). IgG and IgG4 primers for qPCR were designed to specifically amplify sequences that encode the constant region of the heavy chain of the receptor. Additionally, the following rules were applied: (1) 2 different reverse primers were designed, one for all possible IgG subtypes and one specific for the IgG4 subtype, and (2) the 2 reverse primers were designed on virtually the same position to allow comparable conditions. After optimization, this resulted in 1 universal forward primer (5′-GCTGCCTGGTCAAGGACTAC-3′), 1 generic IgG reverse primer (5′-TCTTGTCCACCTTGGTGTTG-3′), and 1 specific IgG4 reverse primer (5′-CTACGTTGCAGGTGTAGGTCTTC-3′). Duplicate qPCR reactions were performed in a 10 μl total volume in the presence of 10 pmol of the forward and reverse primers, cDNA from 50 ng RNA input, and 5 μl of SensiFAST SYBR Lo-ROX reagent (catalog no. BIO-94005, Bioline; GC Biotech, Alphen aan den Rijn, Netherlands) for 40 cycles (95°C for 2 minutes, 40 cycles \[95°C for 5 seconds, 60°C for 10 seconds, and 72°C for 20 seconds\], followed by a melting curve \[95°C for 5 seconds, 65°C for 1 minute, and 97°C continuous\]), using the LightCycler 480 system (Roche Diagnostics, Almere, The Netherlands). Both for IgG and IgG4, the starting concentrations in the sample were calculated using LinRegPCR software15 and used to calculate the percentage of IgG+ RNA molecules that were IgG4+.[@bib12]

Clinical, laboratory, imaging and histo-/cytopathological findings were prospectively collected from all patients investigated and treated. Patients were discussed in a weekly multidisciplinary meeting in the presence of at least 1 surgeon, gastroenterologist, oncologist, pathologist and radiologist. Histo-/cytopathological findings were analyzed in patients who underwent a biopsy, brush or surgical intervention of the biliary tract or pancreas. For the diagnosis of IgG4-RD, the HISORt criteria were used as a reference standard.[@bib15] Malignancy was defined by the presence of neoplastic tissue/cells at histo-/cytopathological examination. Patients with high suspicion of IgG4-RD and no proven malignancy, were treated with prednisolone (30--40 mg daily) for 2--4 weeks and were then re-evaluated by laboratory tests and imaging to monitor tumor response.

Sample size calculation {#sec2.1}
-----------------------

Every year approximately 450--500 patients are seen at the specialized outpatient hepato-pancreato-biliary clinic. Based on the assumption that every year circa 5 new patients with IgG4-RD will present, 1,000 patients had to be screened in 2 years to identify 10 patients with IgG4-RD. In order to evaluate the predictive value of the clinical decision model to distinguish between IgG4-RD of the biliary tract or pancreas and cancer, a minimum of 10 patients with IgG4-RD had to be tested, to allow for 1 false negative result, based on a sensitivity of 94% and a specificity of 99% of the IgG4/IgG RNA ratio. Using the IgG4/IgG RNA ratio alone, we estimated to have 1 false negative and 10 false positive results. However, when combining the accuracy of blood IgG4/IgG RNA ratio for IgG4-RD with brush cytology for cholangiocarcinoma and pancreatic carcinoma (sensitivity 30--50%, specificity 99%), EUS-FNA for pancreatic carcinoma (sensitivity 80%, specificity 100%) and biopsies of presumed metastases, we aimed to lower the number of false positive test results from 10 to 3. On the other hand, 9 patients would be diagnosed correctly with IgG4-RD and would be saved from unnecessary surgery or chemotherapy.

An interim analysis of this open, prospective, single center trial was performed in September 2019 and the study was subsequently stopped on September 10, 2019.

Statistical analysis {#sec2.2}
--------------------

The predictive value of the blood IgG4/IgG RNA ratio was calculated with a true positive test defined as an elevated IgG4/IgG RNA ratio ≥5% in combination with response to prednisolone treatment. A false positive test was defined as an elevated IgG4/IgG RNA ratio ≥5% in combination with a histopathologically proven malignancy or clear evidence of a benign disease different from IgG4-RD. A false negative test was defined as an IgG4/IgG RNA ratio \<5% and benign histo-/cytopathology with histological features of IgG4-RD (tissue infiltration of \>10 IgG4+ plasma cells per high power field (HPF) in biopsy or \>50 IgG4+ plasma cells per HPF in organ resection material, in combination with lymphoplasmacytic infiltration, storiform fibrosis and/or obliterative phlebitis[@bib16]) after biopsy/resection for a presumed malignancy. The test was considered true negative if histo-/cytopathology showed signs of malignancy or clear evidence of a benign disease different from IgG4-RD in combination with an IgG4/IgG RNA ratio ≤5%. Statistical differences between benign and malignant disease for serum levels of IgG4, CA 19.9 and blood IgG4/IgG RNA ratio were evaluated using Wilcoxon-Mann-Whitney test. All statistical testing was 2-sided and performed at the 0.05 significance level (*p* \<0.05) using SPSS version 25 (IBM SPSS statistics).

The study protocol was approved by the Medical Research and Ethics Committee of the Amsterdam UMC, location AMC (W18_263 \# 18.328).

Results {#sec3}
=======

A total of 213 consecutive patients presenting at a specialized multidisciplinary hepato-pancreato-biliary outpatient clinic for suspicion of pancreatobiliary malignancy were investigated between February and September, 2019. One hundred and four patients (48.8%) were male and 109 (51.2%) were female, with a mean (±SD) age of 68 ± 11 years. Demographic, clinical and biochemical characteristics are summarized in [Table 1](#tbl1){ref-type="table"}. A benign disease was diagnosed in 35 patients (16.4%): 7 patients were diagnosed with cholecystitis and/or cholecysto-/choledocholithiasis, 7 patients with chronic pancreatitis or AIP type 2, 10 patients with a pancreas cyst, and 8 patients with other benign diseases or no abnormalities. In this cohort no patients were diagnosed with PSC. Based on clinical, laboratory and imaging findings, 3 patients (1.4%) were diagnosed with IgG4-RD. All 3 patients were male with a mean age of 74 years, the blood IgG4/IgG RNA ratio was elevated (resp. 10.9%, 37.9% and 41.2%) and in 2 of the 3 patients serum IgG4 was more than 10× elevated (\>14.0 g/L). Two patients were treated with prednisolone and subsequently with azathioprine and responded to prednisolone by rapid improvement of laboratory tests and, at imaging, decrease of tumor size and/or bile duct dilatation. One patient suffering from dysregulated diabetes was treated with ursodeoxycholic acid with marked improvement of cholestasis as well. A total of 178 patients were diagnosed with a malignancy, of whom 165 patients had a primary malignancy of the pancreas or biliary tract: 110 patients (51.6%) were diagnosed with pancreatic cancer, 37 patients (17.4%) with cholangiocarcinoma, 11 patients (5.2%) with carcinoma of the papilla of Vater and 7 patients (3.3%) with gallbladder carcinoma.Table 1Clinical and biochemical characteristics of 213 consecutive patients presenting with suspected or proven hepato-pancreato-biliary malignancies.CharacteristicsAge, years \[mean ± SD\]68 ± 11Sex, male/female104 (49%)/109 (51%)Total bilirubin, μmol/L15 (8--95)Alkaline phosphatase, U/L175 (85--395)Gamma-glutamyltransferase, U/L124 (35--511)Aspartate aminotransferase, U/L37 (22--85)Alanine aminotransferase, U/L51 (22--117)IgG4/IgG RNA, %3.9 (2.0--8.0)IgG4, g/L0.48 (0.25--0.88)Carbohydrate antigen 19.9, kU/L127 (19--1,235)[^2]

The blood IgG4/IgG RNA ratio was true positive in 3 patients with IgG4-RD (3.3%) and false positive (median IgG4/IgG RNA ratio 9.8%, IQR 6.3--15.2) in 87 patients (40.8%) with other benign or malignant disease. In 123 patients (58.6%) the test was true negative ([Fig. 1](#fig1){ref-type="fig"}). Receiver operating characteristics (ROC) curve analysis revealed an area under the curve (AUC) for IgG4/IgG RNA ratio of 0.793 to predict IgG4-related disease (sensitivity 100%, specificity 58.6%). No differences were observed in patient characteristics (age, gender, symptoms at presentation, biochemical tests, diagnosis) between patients with a false positive test (n = 87) in comparison to patients with a true negative test (n = 123) ([Table 2](#tbl2){ref-type="table"}).Fig. 1Limited value of elevated blood IgG4/IgG RNA ratio (threshold 5%) in the prospective DIPAC trial to identify patients with IgG4-RD among a patient cohort suspected or proven to suffer from hepato-pancreato-biliary malignancy.Sensitivity was 100%, specificity was 58.6%, the positive predictive value was 3.3%. CA 19.9, carbohydrate antigen 19.9; IgG4-RD, IgG4-related disease.Table 2Comparison of characteristics of patients tested true negative and false positive using IgG4/IgG RNA ratio in blood.Patient characteristicsTrue negative\
n = 123False positive\
n = 87*p* value[∗](#tbl2fnlowast){ref-type="table-fn"}Gender, n (%)0.51 Female61 (49.6%)48 (55.2%) Male62 (50.4%)39 (44.8%)Diagnosis, n (%)0.08 Pancreatic carcinoma61 (49.6%)49 (56.3%) Cholangiocarcinoma26 (21.1%)11 (12.6%) Galbladder carcinoma6 (4.9%)1 (1.1%) Papil carcinoma4 (3.3%)7 (8.0%) Primary malignancy unknown0 (0%)2 (2.3%) Other malignancy5 (4.1%)6 (6.9%) Benign disease21 (17.1%)11 (12.6%)Symptoms, n (%) Jaundice47 (38.2%)28 (32.2%)0.45 Abdominal discomfort80 (65.0%)48 (55.2%)0.19 Pruritus23 (18.7%)26 (29.9%)0.09 Fever3 (2.4%)0 (0%)0.38 Decreased appetite39 (31.7%)24 (27.6%)0.63 Weight loss67 (54.5%)51 (58.6%)0.48Age, mean (SD)67.4 (11.8)67.7 (11.0)0.85Biochemical tests, mean (SD) C-reactive protein19.9 (29.0)17.7 (29.2)0.59 Bilirubin88.3 (142)95.1 (146)0.74 Alkaline phosphatase306 (318)297 (321)0.85 Gamma-glutamyltransferase364 (511)353 (541)0.88 Aspartate aminotransferase68 (74)71 (77)0.78 Alanine aminotransferase103 (150)112 (160)0.67 Carbohydrate antigen 19.92,110 (8,160)2,200 (7,170)0.94 IgG40.59 (0.55)0.69 (0.58)0.25[^3][^4]

CA19.9 differentiated benign and malignant diseases (*p* \<0.01), but no difference in serum IgG4 or blood IgG4/IgG RNA ratio (*p* = 0.6, each) between these groups was observed ([Table 3](#tbl3){ref-type="table"}). An AUC for CA19.9 of 0.721 to predict malignant disease in this cohort (sensitivity 73.6%, specificity 70.6%) was reached.Table 3Discriminant function of laboratory tests for benign *vs.* malignant hepato-pancreato-biliary disease in 213 consecutive patients presented at a specialized multidisciplinary outpatient clinic.Benign disease\
(n = 35)Malignant disease\
(n = 178)*p* valueIgG4/IgG RNA ratio, %4.0 (2.1--6.9)3.9 (2.0--8.2)0.6IgG4, g/L0.4 (0.3--1.1)0.5 (0.2--0.9)0.6CA 19.9, kU/L16.5 (7--50)201 (33--1,646)\<0.01[^5]

Discussion {#sec4}
==========

In patients presenting at a dedicated outpatient clinic with suspected or proven biliary or pancreatic cancer, the accuracy of an elevated IgG4/IgG RNA ratio to discriminate pancreatic and biliary cancer from IgG4-RD was poor, as demonstrated in this open prospective DIPAC trial. The results of the interim analysis led us to stop the trial and advise against the use of this test for discrimination of IgG4-RD from biliary and pancreatic malignancies outside a research setting. Retrospective re-analysis of a large cohort of hepato-pancreato-biliary patients is underway to understand the discrepancy between previous[@bib12] and actual results regarding a diagnostic value of the blood IgG4/IgG RNA ratio.
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